WUXI06:BKK
Wuxi Biologics (Cayman) Inc. KKPS DR
THB 5.30
arrow_upward
+1.92%(+0.10) 1 日
10月15日, 12:08:36 GMT+7 · THB
search
すべての記号
| 記号 | 価格 | 変化 | 変化率 |
|---|
insights_autoWUXI06 の上位の分析情報を生成しています...
始値
THB 5.25
高値
THB 5.35
安値
THB 5.25
時価総額
2025.45億
平均出来高
9.36万
取引量
22.25万
52 週高値
THB 6.25
52 週安値
THB 3.02
発行済株式数
41.17億
従業員数
1万
始値
THB 5.25
高値
THB 5.35
安値
THB 5.25
時価総額
2025.45億
平均出来高
9.36万
取引量
22.25万
52 週高値
THB 6.25
52 週安値
THB 3.02
発行済株式数
41.17億
従業員数
1万
ニュース記事
情報源: ウェブソース、ニュース パートナー
株探
·
1 時間前
米国株見通し：下げ渋りか、好業績銘柄が相場を下支え
Yahoo!ファイナンス
·
4 時間前
15日のインド市場見通し：売り先行か、内外の利上げ懸念が圧迫材料へ(フィスコ)
京都新聞デジタル
·
9 時間前
ＮＹ株続落、４８ドル安
プロフィール
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Wuxi Biologics (Cayman) Inc. KKPS DR について